Is a central action of acute antimigraine drugs essential?
Goadsby
P J
PJ
Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D001921:Brain / Q000187:drug effects*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D010080:Oxazoles / Q000627:therapeutic use; D023303:Oxazolidinones; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin / Q000187:drug effects; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D014363:Tryptamines
D000700:Analgesics; C470302:HTR1B protein, human; D010080:Oxazoles; D023303:Oxazolidinones; D044302:Receptor, Serotonin, 5-HT1B; D044346:Receptor, Serotonin, 5-HT1D; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan